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AbstrAct
Objective: the use of antipsychotics to treat 
seniors in long-term care facilities (LtcFs) has raised 
concern because of health consequences (i.e., 
increased risk of falls, stroke, death) in this vulner-
able population. this study measured geographic 
patterns of antipsychotic utilization among seniors 
living in LtcFs in Newfoundland and Labrador (NL) 
and assessed potential inappropriateness.
Method: We analyzed prescription records among 
adults 66 years and older with provincial pre-
scription drug coverage admitted to LtcFs in NL 
between April 1, 2011, and March 31, 2014. Patterns 
of use were analyzed across the 4 regional health 
authorities (rHAs) in NL and LtcFs. Logistic, Poisson 
and linear regression models were used to test vari-
ations in prevalence, rate and volume of antipsy-
chotic utilization. to assess potential inappropriate-
ness of antipsychotic use, we analyzed data from 
resident Assessment Instrument–Minimum Data 
set (rAI-MDs) 2.0 forms from NL LtcFs between 
January 1, 2016, and December 31, 2018. Pearson 
chi-squared analysis was performed at the rHA and 
LtcF levels to determine changes in percentage of 
total prescriptions or antipsychotic prescriptions 
without psychosis.
Results: between 2011 and 2014, 2843 seniors 
were admitted to LtcFs across NL; of these, 1323 
residents were prescribed 1 or more antipsychotics. 
Within the 3-year period, the percentage of anti-
psychotic use across facilities ranged from 35% to 
78%. Using data from 27,260 rAI-MDs 2.0 assess-
ments between 2016 and 2018, 71% (6995/9851) 
of antipsychotic prescriptions were potentially 
inappropriate.
Discussion: there is substantial variation across NL 
regions concerning the utilization of antipsychotics 
for senior in LtcFs. Facility size and management 
styles may be reasons for this.
Conclusion: With nearly three-quarters of antipsychotic prescriptions shown to be potentially inappropri-
ate, systematic interventions to assess indications for antipsychotic use are warranted. Can Pharm J (Ott) 
2021;154:xx-xx.
I undertook this research 
as part of my master’s 
degree in epidemiology 
at Memorial University. 
I have an interest in both 
psychiatric conditions 
and the off-label use of 
psychiatric medications, 
and this study allowed me 
to combine both of these 
interests.
J’ai entrepris cette 
recherche dans le 
cadre de ma maîtrise 
en épidémiologie à 
l’Université Memorial. Je 
m’intéresse à la fois aux 
troubles psychiatriques 
et à l’utilisation non 
indiquée des médicaments 
psychiatriques, et cette 
étude m’a permis de 
combiner ces deux champs 
d’intérêt. 
Zachary E. M.  
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Introduction
The high rates of potentially inappropriate antipsychotic pre-
scriptions among seniors have been well documented in Can-
ada and in other parts of the world.1-3 While approximately 5% 
of community-dwelling seniors receive antipsychotics,2 the 
prevalence of antipsychotic prescription in long-term care for 
2016-2017 was estimated to be 21% nationally and 38% in New-
foundland and Labrador (NL).3 Many residents in long-term 
care facilities (LTCFs) are prescribed antipsychotics to treat the 
behavioural and psychological symptoms of dementia.4 This is 
despite Health Canada warnings regarding the risks of using 
atypical antipsychotics in elderly persons. Furthermore, only 
1 antipsychotic agent (risperidone) is labeled for the treatment 
of dementia and only for the short-term management of severe 
behavioural problems.5
Studies conducted elsewhere in the world have shown sub-
stantive variation in prescribing practices for antipsychotics 
in LTCFs across regions.6-9 In Ontario, a study of residents in 
LTCFs found some variation between the different regions of the 
province in terms of antipsychotic prescriptions, ranging from 
25.4% to 32.4%.10 A report published by the Canadian Institute 
for Health Information (CIHI) reported antipsychotic prescrib-
ing rates in nursing homes in 5 provinces (Prince Edward Island 
[PEI], New Brunswick, Manitoba, Ontario and British Colum-
bia) from 2006 to 2014. As of 2014, Manitoba had the lowest rate 
of the 5 provinces, at 32%, and New Brunswick had the highest 
rate at over 50%.11 Similarly, a study conducted across multiple 
states in the United States found that antipsychotic prescription 
in LTCFs was significantly influenced by region and increased 
significantly as size of the facility increased.12
Given the high rates of antipsychotic use previously 
reported by the CIHI, we sought to 1) estimate the geographic 
variation in antipsychotic utilization across the 4 regional 
health authorities (RHAs) of NL and 2) report the proportion 
of antipsychotic use without signs of psychosis among seniors 
living in LTCFs in NL. Geographic variation was examined to 
identify potential areas in which to pursue additional study.
Methods
Data sources and study population
This study was composed of 2 different parts, both estimating 
variation in antipsychotic use. In the first part of the study, a 
cohort of LTCF residents in NL 66 years and older was identi-
fied who, between April 1, 2011, and March 31, 2014, received 
publicly funded drug coverage for eligible prescriptions, includ-
ing antipsychotics, under the 65Plus Plan provided by the New-
foundland and Labrador Prescription Drug Program (NLPDP). 
This cohort was identified using provincially maintained health 
care databases linked and provided by the Newfoundland and 
Labrador Centre for Health Information (NLCHI).
The NLPDP was accessed to obtain prescription records for 
individuals receiving the Guaranteed Income Supplement (GIS) 
and Old Age Security (OAS) benefits. Approximately 80% of 
seniors in the province receive GIS due to their income being 
less than the federally set minimum.13 Information collected by 
the NLPDP database includes drug dispensed, date of dispensa-
tion, drug dosage, quantity dispensed and days’ supply. The Pro-
vincial Client Registry, which contains personal demographic 
information such as Medical Care Plan (MCP) number, sex, 
month and year of birth and postal code, was also used. Last, 
the Long-Term Care (LTC) Module of the Provincial Meditech 
database, containing information on seniors living in LTCFs as 
well as their dates of admission and discharge, was linked.
KNoWLeDge INto PrActIce 
 • It is well known that overuse of antipsychotics is com-
mon among canadian seniors living in long-term care 
facilities.
 • this study found a wide variation in the prevalence of 
seniors in long-term care facilities being prescribed 
antipsychotics across the 4 regional health authorities 
of the province.
 • the results also indicate a high (but decreasing) preva-
lence of potentially inappropriate antipsychotic pre-
scription across the 4 health authorities.
 • the role of pharmacists as medication experts is essen-
tial in the ongoing effort to reduce the high prevalence 
of potentially inappropriate antipsychotic prescribing 
in the province.
MIse eN PrAtIQUe Des 
coNNAIssANces                                 
 • Il est bien connu que la surconsommation 
d’antipsychotiques est courante chez les personnes 
âgées canadiennes vivant dans des établissements de 
soins de longue durée.
 • cette étude a révélé une grande variation dans 
la prévalence des personnes âgées dans les 
établissements de soins de longue durée qui se voient 
prescrire des antipsychotiques dans les quatre autorités 
régionales de la santé de la province.
 • Les résultats indiquent également une prévalence 
élevée (mais décroissante) de la prescription 
potentiellement inappropriée d’antipsychotiques dans 
les quatre autorités sanitaires.
 • Le rôle des pharmaciens en tant qu’experts en médication 
est essentiel dans l’effort continu pour réduire la 
prévalence élevée de la prescription potentiellement 
inappropriée d’antipsychotiques dans la province.
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Each database contained a deidentified unique patient num-
ber to allow for linkage between databases. Only patients living 
in the provincially funded LTCFs were included in the study, 
thereby excluding the privately funded personal care homes 
(PCHs). Patients were also excluded from the study cohort if 
they spent longer than 7 consecutive days outside an LTCF, so 
as not to confound the data. This study has been approved by 
the Health Research Ethics Authority of Newfoundland and 
Labrador (HREB #2016.324).
For the second part of the study, antipsychotic use and appro-
priateness were estimated for all residents in LTCFs in NL who 
had quarterly Resident Assessment Instrument–Minimum Data 
Set (RAI-MDS) 2.0 forms completed between January 1, 2016, 
and December 31, 2018. The RAI-MDS 2.0 assessments are com-
pleted by a case manager (usually a nurse or a social worker) for 
each resident at each facility. These assessments are the standard-
ized tool for assessing residents upon their admission to the LTCF, 
any significant change in health status and at the end of every cal-
endar quarter, meaning that the progress of a single resident can 
be tracked over time. Data from this assessment include age, sex, 
month of assessment, if antipsychotics were prescribed and if the 
prescription was potentially inappropriate. All data for the RAI-
MDS are collected in person. The initial assessment of residents 
upon admittance to LTCFs was not included to give facilities 1 
quarter to safely discontinue any antipsychotics if required.
If a prescription for antipsychotics was noted in the RAI-
MDS 2.0, the reason for the prescription was examined. 
Acceptable indicators for prescribing antipsychotics according 
to CIHI are a diagnosis of schizophrenia, Huntington chorea, 
delusions/hallucinations and/or the treatment of end-of-life 
residents.14 If none of these indications were noted in the 
assessment, the prescription was flagged as potentially inap-
propriate. This list is not inclusive of all possible indicators for 
appropriate antipsychotic prescription. Therefore, the term 
potentially inappropriate must be used to describe prescrip-
tions for patients without indications stated above.
Definitions of geographic regions
Seniors living in LTCFs were categorized by location in 1 of the 
4 regional health authorities (RHAs) in the province: Eastern 
Health, Central Health, Western Health or Labrador-Grenfell 
Health. Of the 4 RHAs, Eastern Health is the largest by popula-
tion, serving approximately 300,000 people in the eastern part 
of the island with 8 hospitals, 7 health centres and 15 LTCFs.15 
Central Health serves roughly 95,000 people in the central 
region of the island with 2 hospitals, 9 community health cen-
tres and 11 LTCFs.15 Western Health serves roughly 78,000 
people in western Newfoundland and most of the northern 
peninsula with 2 hospitals, 4 health centres and 6 LTCFs.15 
Labrador-Grenfell Health serves roughly 37,000 people in Lab-
rador and the top of the northern peninsula with 3 hospitals, 
3 health centres and 4 LTCFs.15 Each LTCF in the 4 RHAs was 
randomly assigned a number to maintain anonymity.
Measuring drug utilization
For the first part of the study, all residents who received 1 or 
more antipsychotic prescriptions during the 3-year period were 
defined as users. The database detailed the specific drug each 
senior received as well as the strength of each dose. All analy-
ses were performed using the total number of residents receiv-
ing antipsychotic medications from 2011 to 2014. Each drug 
was identified by its Anatomical Therapeutic Chemical (ATC) 
code. Drug utilization for antipsychotic prescriptions was 
measured using 3 metrics: 1) prevalence of use was calculated 
as the ratio of total number of users per quarter for antipsy-
chotics over total number of NLPDP beneficiaries per quarter, 
2) the rate of use was calculated as the ratio of the number 
of antipsychotic prescription records per 1000 total prescrip-
tions per quarter and 3) volume of use was calculated based 
on total number of defined daily doses (DDDs) per quarter per 
drug. The World Health Organization (WHO) defines DDD 
as the “assumed average dose per day of a drug in adults, as 
prescribed for its main indication.”16 Total DDD is calculated 
by obtaining the product of the dose strength and the number 
of days’ supply, then dividing by 1 DDD.16 Chronic users of 
antipsychotics (defined as receiving 2 or more prescriptions 
for 2 or more consecutive quarters) were specifically identified.
For the second part of the study, RAI-MDS 2.0 assessments 
were analyzed to determine overall prevalence of antipsychotic 
prescriptions as well as prevalence of potentially inappropriate 
prescriptions. Prevalence of antipsychotic use was calculated 
for each quarter of the years 2016 to 2018 as the ratio of assess-
ments including a prescription for antipsychotics over the total 
number of assessments. The prevalence was analyzed over a 
3-year period. The prevalence of potentially inappropriate pre-
scriptions was calculated for each quarter as the ratio of assess-
ments with no appropriate prescription for antipsychotics over 
the total number of assessments with prescriptions for antipsy-
chotics. If a prescription for antipsychotics was noted in the 
RAI-MDS 2.0, the reason for the prescription was examined 
and noted to be acceptable only if 1 or more of the indicators 
in the CIHI criteria were present.14
Statistical analysis
Descriptive statistics were used to summarize the study pop-
ulation characteristics across RHAs. Differences in patient 
characteristics between geographic regions for continuous 
variables were examined by t-test, and discrete variables were 
tested using chi-squared tests.
Multivariable logistic regression models were used to test 
regional differences in the prevalence of seniors receiving anti-
psychotics (dichotomous variable). Poisson regression models 
were used to analyze differences in the rate of prescriptions 
among regions. Linear regression models were used to mea-
sure differences in volume across geographic locales. The pri-
mary variable for modelling was RHA, with results indicating 
a p-value, odds ratio (or difference if linear regression) and a 
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95% confidence interval. In addition to comparing differences 
among RHAs, variation across individual facilities where at 
least 30 residents received antipsychotic prescriptions was 
measured for prevalence, rate and volume.
For the multivariate analyses, age, sex and chronic disease 
score (CDS) were used as covariates in the models. CDS is a 
prescription-based comorbidity score where 1 point is given 
to an individual corresponding to each drug class they are 
prescribed, with a maximum score of 24 points. An increased 
CDS is associated with increased risk of 1-year all-cause hos-
pitalization and mortality.17 Age was measured as a continu-
ous variable and sex as a binary variable (male = 0, female = 
1), as it was recorded in the data set. Potential interactions 
between facility size and prevalence were also analyzed. Test-
ing was completed on all models as well as the 2-way interac-
tions for the 3 variables used in the models. No violations of 
the assumptions for the 3 regression models were found.
For the second study, a Pearson chi-squared analysis was 
performed on the provincial as well as individual RHA results 
to determine any statistically significant changes in prevalence 
of total or potentially inappropriate antipsychotic prescriptions.
All statistical analyses were conducted using SPSS, version 
23 (SPSS, Inc., Chicago, IL).
Results
Long-term care facilities in the province by region
Using the prescription claims-based cohort, we identified a 
total of 2843 residents in the LTCFs across the 4 RHAs, 1323 
of whom received prescriptions for antipsychotics (Table 1). 
Of those residents receiving antipsychotics, 1134 (86%) were 
chronic users. There were no noticeable differences in the 
patterns of use for short-term and chronic users of antipsy-
chotics. Of the 21,495 antipsychotic prescriptions written in 
the 3-year period, nearly all were for a 1-month period. The 
prevalence, rate and volume of antipsychotic prescriptions in 
the RHAs were highest in Eastern Health and lowest in Lab-
rador-Grenfell Health and remained relatively stable over the 
3-year period from 2011 to 2014 (Table 1). The median age of 
the residents in each of the RHAs was between 83 and 86 years, 
and the prevalence of males in long-term care was between 23% 
and 35%. The median CDS was 5.00 in Eastern Health, Cen-
tral Health and Western Health and 4.50 in Labrador-Grenfell 
Health. None of the differences in demographic information 
was statistically significant. After controlling for age, sex and 
CDS, there was no significant difference in the prevalence, rate 
or volume between Eastern Health and the other RHAs (p = 
0.120, p = 0.125 and p = 0.088, respectively).
Province-wide, 27,260 RAI-MDS 2.0 assessments were ana-
lyzed over a 3-year period from 2016 to 2018 in the 35 provin-
cially funded LTCFs. Out of the total number of assessments, 8718 
were completed in 2016, 9190 in 2017 and 9352 in 2018. Dur-
ing these 3 years, 3377 (39%) assessments in 2016, 3398 (37%) 
assessments in 2017 and 3076 (33%) assessments in 2018 showed 
a prescription for antipsychotics. Of the assessments showing a 
prescription for antipsychotics, 2467 (73%) assessments in 2016, 
2498 (74%) assessments in 2017 and 2030 (66%) assessments in 
2018 were deemed to be potentially inappropriate. The decrease 
in the total number of assessments with antipsychotics prescribed 
between 2016 and 2018 was shown to be statistically significant by 
a Pearson chi-squared test (p < 0.05). The decrease in the number 
of assessments with potentially inappropriate antipsychotic pre-
scriptions between 2016 and 2018 was also statistically significant.
Variation in antipsychotic utilization across LTCFs
Using the claims-based cohort and controlling for age, sex 
and CDS, the difference in prevalence between facilities for 
antipsychotic prescription was significant (p < 0.001), with 
a 2-fold relative variation (Figure 1A). There was no interac-
tion between facility and age, sex or CDS. After controlling 
for age, sex and CDS, neither rate nor volume of antipsychotic 
prescriptions was statistically significant across the facilities 
(p = 0.248 and p = 0.087, respectively) (Figure 1B,C). Since 
no facilities in the Labrador-Grenfell region had 30 or more 
residents receiving antipsychotics, the region was not included 
in the attached figures.
For the second part of the study, the prevalence of anti-
psychotic use in Eastern Health LTCFs ranged from 14.7% to 











residents in long-term care facilities 1983 659 153 48
Prevalence of residents receiving antipsychotics,  
n (% residents)
952 (48%) 285 (43%) 69 (45%) 17 (35%)
rate of antipsychotic prescriptions per 1000 total 58 47 50 50
Volume of antipsychotic prescriptions as defined daily 
doses/1000 people/day
95 65 62 52
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80.0% over the 3-year period, with a mean of 40.7% in 2016, 
39.2% in 2017 and 35.0% in 2018 (Figure 2). The percentage of 
potentially inappropriate antipsychotic prescriptions ranged 
from 38.9% to 100.0% over the 2-year period, with a mean 
of 71.4% in 2016, 72.3% in 2017 and 63.8% in 2018 (Figure 
3). The prevalence of antipsychotic use in Central Health 
LTCFs over the 3-year period ranged from 8.9% to 63.9%, 
and the percentage of potentially inappropriate antipsychotic 
prescriptions ranged from 7.1% to 100.0%. The prevalence of 
antipsychotic use in Western Health LTCFs over the 3-year 
FiGuRe 1 (A) Prevalence of residents in long-term care receiving one or more antipsychotic 
prescriptions by facility. (b) rate of antipsychotic prescriptions filled in long-term care per 1000 total 
prescriptions by facility. (c) Volume of antipsychotic prescriptions filled in long-term care by facility 
measured as defined daily doses per 1000 people per day
35% 37%
39% 41% 41%
44% 44% 44% 45%



































































































cHF, central Health facility; eHF, eastern Health facility; WHF, Western Health facility.
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period ranged from 10.4% to 49.4%. The percentage of poten-
tially inappropriate antipsychotic prescriptions ranged from 
33.3% to 100.0%. The prevalence of antipsychotic use in Lab-
rador-Grenfell Health LTCFs over the 3-year period ranged 
from 16.7% to 64.0%, and the prevalence of potentially inap-
propriate antipsychotic prescriptions ranged from 58.9% to 
100.0%.
Discussion
Our findings in both parts of the study suggest substantial vari-
ation exists across LTCFs for the use of antipsychotic medica-
tions. These findings also indicate the high level of potentially 
inappropriate use of antipsychotics in LTCFs in the province. 
However, some consolation can be found in the fact that these 
prevalences are decreasing over time in all 4 RHAs.
One factor that may contribute to the difference in preva-
lence of antipsychotic prescriptions is facility size. As shown in 
the study by Chen et al.,12 facility size is significantly and posi-
tively correlated to prevalence of psychoactive drug prescrip-
tions. Eastern Health houses 70% of facility-dwelling seniors 
and administers 9 of the 10 largest facilities in the province. 
Study results show that the region also has the highest preva-
lence of antipsychotic prescription.
In contrast to the first study, LTCFs in Labrador-Grenfell 
Health had the highest prevalence of antipsychotic prescrip-
tions between 2016 and 2018. A possible reason for this is the 
difference in the information collected in the 2 studies, with 
study 1 collecting data from residents 66 years or older and on 
the NLPDP. Study 2, on the other hand, collected information 
on all LTCF residents.
A more intangible factor to explain differences in utilization 
patterns is the work culture of the RHAs and their individual 
facilities. Hughes et al.18 wrote that the individual culture of a 
facility greatly influences the running of the facility, including 
which residents do or do not receive prescriptions for poten-
tially harmful medications. Various agencies in Canada have 
addressed ways to change facility culture to implement health-
ier prescribing practices. These include agreeing on appro-
priateness criteria, establishing regular reviews and pursuing 
nonpharmacologic interventions.19,20
FiGuRe 2 Percentage of residents receiving antipsychotic prescriptions by regional health authority 


































FiGuRe 3 Percentage of antipsychotic prescriptions that were potentially inappropriate by regional 
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In 2015, the Western and Central Health RHAs initiated a 
deprescribing program in their LTCFs in conjunction with the 
Canadian Foundation for Health Care Improvement (CFHI).21 
The program was aimed specifically at discontinuing inappro-
priate antipsychotic prescriptions within LTCFs. Nationally, 2 
studies released by the Canadian Institute for Health Informa-
tion11,22 have indicated that total prevalence of antipsychotic 
prescriptions for seniors has decreased in some provinces (e.g., 
Ontario and Manitoba) but increased in others (e.g., all Atlantic 
provinces). The high median age of the population in the Atlantic 
provinces may be contributing to this phenomenon,23 as well as 
more developed policies being put in place by other provinces.20
Solutions are not always simple, however. Behavioural 
interventions often require a high staff-to-resident ratio to 
personalize the health care management of residents. A lack 
of human resources means that staff working in LTCFs may 
have few alternatives to the prescription of antipsychotics to 
treat behavioural symptoms in residents. Interventions may, 
however, be available from outside the LTCFs. The Medication 
Therapy Services (MTS) clinic operated by the School of Phar-
macy at Memorial University offers services to patients in the 
community, their doctors and other health providers, to help 
them receive the medications that are best for them.24 Starting 
in 2017, a pilot study was launched by the MTS clinic to pro-
vide deprescribing services to residents in LTCFs.25
Limitations
The first part of the study included residents covered under 
NLPDP and living in government-funded LTCFs. As well 
as excluding all residents in private facilities, the study also 
excludes seniors ineligible for prescription drug coverage 
under NLPDP. Approximately 80% of seniors in Newfound-
land and Labrador receive coverage from this program.13 
Since the Western and Labrador-Grenfell Health regions had 
relatively fewer residents (together constituting only 7% of the 
total number of residents), some results from the regression 
analyses may have less precision than the results from the East-
ern and Central RHAs. In addition, all LTCFs were included in 
this analysis, even those where there were very few residents 
receiving antipsychotic prescriptions. While this information 
is important in order to understand the utilization of antipsy-
chotics in all facilities in the province, the results may again not 
be as precise as in larger facilities. Finally, there were seniors 
who had to be removed from both parts of the study because 
their relevant data were missing or could not be used. It is 
unlikely that those excluded from the study had any real effect, 
as the number of those excluded was less than 2% of the total 
and their demographic characteristics were similar to those 
included in the study.
For the second study, in keeping with CIHI guidelines,14 the 
use of antipsychotics was deemed appropriate only for end-of-
life residents and residents with psychosis. This excludes the 
accepted short-term use of antipsychotics to manage inappro-
priate behaviours, such as aggression,5 in residents. Limita-
tions that affect both studies include no clinical indication for 
the prescription of antipsychotics, no data on the specialty of 
the prescribing physician and no data on the clinical outcomes 
of the resident being treated with antipsychotics to monitor 
effectiveness or tolerability.
Conclusions
These analyses were designed to measure geographic varia-
tion of antipsychotic prescriptions among residents in LTCFs 
in Newfoundland and Labrador. It was found that the preva-
lence of antipsychotic prescriptions was significantly different 
across geographic regions in LTCFs but also has been decreas-
ing in recent years in each of the 4 RHAs. The prevalence of 
the potentially inappropriate prescription of antipsychotics has 
similarly decreased in all RHAs during the 3-year period of 
measurement from 2016 to 2018. ■
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